The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Abstract
BACKGROUND: Current antipsychotics have only a limited effect on 2 core aspects of schizophrenia: negative symptoms and cognitive deficits. Minocycline is a second-generation tetracycline that has a beneficial effect in various neurologic disorders. Recent findings in animal models and human case reports suggest its potential for the treatment of schizophrenia. These findings may be linked to the effect of minocycline on the glutamatergic system, through inhibition of nitric oxide synthase and blocking of nitric oxide-induced neurotoxicity. Other proposed mechanisms of action include effects of minocycline on the dopaminergic system and its inhibition of microglial activation. OBJECTIVE: To examine the efficacy of minocycline as an add-on treatment for alleviating negative and cognitive symptoms in early-phase schizophrenia. METHOD: A longitudinal double-blind, randomized, placebo-controlled design was used, and patients were followed for 6 months from August 2003 to March 2007. Seventy early-phase schizophrenia patients (according to DSM-IV) were recruited and 54 were randomly allocated in a 2:1 ratio to minocycline 200 mg/d. All patients had been initiated on treatment with an atypical antipsychotic < or = 14 days prior to study entry (risperidone, olanzapine, quetiapine, or clozapine; 200-600 mg/d chlorpromazine-equivalent doses). Clinical, cognitive, and functional assessments were conducted, with the Scale for the Assessment of Negative Symptoms (SANS) as the primary outcome measure. RESULTS: Minocycline was well tolerated, with few adverse events. It showed a beneficial effect on negative symptoms and general outcome (evident in SANS, Clinical Global Impressions scale). A similar pattern was found for cognitive functioning, mainly in executive functions (working memory, cognitive shifting, and cognitive planning). CONCLUSIONS: Minocycline treatment was associated with improvement in negative symptoms and executive functioning, both related to frontal-lobe activity. Overall, the findings support the beneficial effect of minocycline add-on therapy in early-phase schizophrenia. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00733057.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Various clinical trials have been conducted using minocycline alone or as an adjunct to risperidone in patients with schizophrenia and have demonstrated overall improvement in negative symptoms and executive functioning (Miyaoka et al., 2008; Levkovitz et al., 2010; Khodaie-Ardakani et al., 2014).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Levkovitz et al., 2010
In the citing paper
“The sole exception was a trial29 that assessed the effects of a 6-month add-on treatment with either minocycline or placebo on cognitive impairment in young subjects in early phase schizophrenia, aged 18–35 years.”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• Minocycline showed a beneficial effect on negative symptoms and general outcome (evident in SANS, Clinical Global Impressions scale).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• Overall, the findings support the beneficial effect of minocycline add-on therapy in early-phase schizophrenia.”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• A similar pattern was found for cognitive functioning, mainly in executive functions (working memory, cognitive shifting, and cognitive planning).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“A trial performed in younger subjects with recent illness onset29 may yield more positive results than those conducted in patients with an average illness duration of >20 years (See table 1).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“add-on administration of minocycline for 22 weeks was associated with improvements in executive functions in individuals with early-phase schizophrenia [107].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [107]
Citations
Cites
Maximum Likelihood from Incomplete Data Via the EM Algorithm
Dempster, A. P., Laird, N. M., & Rubin, D. B. (1977) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1977.tb01600.x · Cited by 50,444
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Miyake, A., Friedman, N. P., Emerson, M. J., Witzki, A. H., Howerter, A., & Wager, T. D. (2000) · Cognitive Psychology · doi:10.1006/cogp.1999.0734 · Cited by 15,798
Missing data: our view of the state of the art
Schafer, J. L., & Graham, J. W. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.2.147 · Cited by 11,638
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Physiologic Dysfunction of Dorsolateral Prefrontal Cortex in Schizophrenia
Weinberger, D. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020020004 · Cited by 2,025
Negative v Positive Schizophrenia
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070025006 · Cited by 2,008
Executive Function and the Frontal Lobes: A Meta-Analytic Review
Alvarez, J. A., & Emory, E. (2006) · Neuropsychology Review · doi:10.1007/s11065-006-9002-x · Cited by 1,981
Cited by
Sorted by citations
Items 301–390 of 390
Hashimoto, K. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.021 · Cited by 7
Update on New and Emerging Treatments for Schizophrenia
Gopalakrishna, G., Ithman, M., & Lauriello, J. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.01.005 · Cited by 6
McGuinness, B. W., & Harkin, A. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_3 · Cited by 7
Herrero-Zazo, M., Brauer, R., Gaughran, F., Howard, L. M., Taylor, D. M., & Barlow, D. J. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117743483 · Cited by 6
Antibiotic exposure is associated with decreased risk of psychiatric disorders
Kerman, I. A., Glover, M. E., Lin, Y., West, J. L., Hanlon, A. L., Kablinger, A. S., & Clinton, S. M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1290052 · Cited by 7
Minocycline and the risk of acute psychiatric events in adolescence: A self-controlled case series
Brauer, R., Herrero-Zazo, M., Barlow, D. J., Gaughran, F., Taylor, D. M., & Howard, L. M. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118821852 · Cited by 5
Redox and Microglia in the Pathophysiology of Schizophrenia
Kato, T. A., Hyodo, F., Yamato, M., Utsumi, H., & Kanba, S. (2015) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.14-00235-4 · Cited by 5
Immune-Based Therapies for Traumatic Brain Injury: Insights from Pre-Clinical Studies
Machado, C. A., Silva, A. C. S. E., de Miranda, A. S., Cordeiro, T. M. E., Ferreira, R. N., de Souza, L. C., Teixeira, A. L., & de Miranda, A. S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190710173234 · Cited by 5
da Silva, N. R., Gobbo, D., Gomes, F. V., Scheller, A., Kirchhoff, F., Bel, E. D., & Guimarães, F. S. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149772 · Cited by 4
Immunomodulation as Therapeutic Approach in Schizophrenia and Depression: State of the Art
Müller, N. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_17 · Cited by 4
Arolt, V., & Ambrée, O. (2013) · Modern trends in psychiatry · doi:10.1159/000343972 · Cited by 4
Neuroinflammation in Schizophrenia Focused on the Pharmacological and Therapeutic Evidence
Xu, H. (2015) · Pharmacologia · doi:10.5567/pharmacologia.2015.438.453 · Cited by 4
Inflammation and Immunity in Schizophrenia
Müller, N. (2021) · Springer eBooks · doi:10.1007/978-3-030-71229-7_14 · Cited by 4
Metabolic syndrome in schizophrenia: Theoretical, clinical and translational perspectives
Agarwal, S. M., & Venkatasubramanian, G. (2013) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.116231 · Cited by 4
Therapeutic Considerations in Individuals at Clinical Risk for Developing Psychosis
Singh, F., DeJoseph, M. L., & Cadenhead, K. S. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0009-2 · Cited by 4
Neurocognition and Treatment Outcomes in Schizophrenia
Molina, J. L., & Tsuang, M. T. (2020) · Springer eBooks · doi:10.1007/978-3-030-19847-3_5 · Cited by 4
Neurodevelopmental and Neuropsychiatric Disorders
Monji, A., Maezawa, I., Mizoguchi, Y., Kato, T. A., & Jin, L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1429-6_14 · Cited by 4
Immunoinflammatory Therapies in Psychiatry: Current Evidence Base
Menon, V., & Ameen, S. (2017) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_505_17 · Cited by 4
Overactivation of Microglia as a Shared Pathophysiology in Different Neuropsychiatric Disorders
Eltokhi, A. (2024) · Integrated science · doi:10.1007/978-3-031-72079-6_11 · Cited by 3
Recent Advances in Schizophrenia Genomics and Emerging Clinical Implications
Bigdeli, T. B., & Harvey, P. D. (2025) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2025.01.008 · Cited by 3
So, M. T.-W., Ullah, A., Waris, A., & Alhumaydhi, F. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199814 · Cited by 4
Brain Damage and Alcohol Dependence: How One May Influence the Other
Syapin, P. J. (2011) · Alcoholism Treatment Quarterly · doi:10.1080/07347324.2011.557985 · Cited by 3
Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology
Müller, N. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_2-1 · Cited by 3
Assessment of Innovative Pharmacological Targets in Schizophrenia
de Sousa, T. R., Ribeiro, M., & Novais, F. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00324-x · Cited by 5
Acute Management of Schizophrenia
Janicak, P. G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0656-7_7 · Cited by 3
Arabzadeh, S., Zeinoddini, A., Mostafavi, S., Hamedi, M., Ehyaii, A., Ghaleiha, A., Zeinoddini, A., & Akhondzadeh, S. (2018) · Europe PMC (PubMed Central) · Cited by 3
C-Reactive Protein and Aggression in Patients with Schizophrenia
Kachouchi, A. (2019) · International Journal of Psychological and Brain Sciences · doi:10.11648/j.ijpbs.20190402.11 · Cited by 3
The Psychotic Face of the Immune System: Inflammation and Schizophrenia
Meyer, U. (2013) · doi:10.1002/9781118314814.ch21 · Cited by 3
Aretouli, E., & Ojeda, N. (2019) · Springer eBooks · doi:10.1007/978-3-319-69892-2_963-1 · Cited by 3
Búsqueda De Nuevos Biomarcadores De La Cognición En Esquizofrenia
Penadés, R., García‐Rizo, C., Bioque, M., González-Rodríguez, A., Cabrera, B., Mezquida, G., & Bernardo, M. (2015) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2015.06.002 · Cited by 2
Combination and augmentation strategies in treatment-resistant schizophrenia
Englisch, S., & Zink, M. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.09.002 · Cited by 2
Şizofrenide Kombinasyon Tedavileri
Altınyazar, V., & Yüksel, N. (2011) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20110701011007 · Cited by 2
Fotinos, A., Zhu, Y., Mao, L. L. J., Atassi, N., Zhou, E., Ahmad, S., Guan, Y., Berry, J. D., Cudkowicz, M., & Wang, X. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_51 · Cited by 2
Neff, A. S. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.02.002 · Cited by 2
Add-On Pharmacotherapy in Schizophrenia: Does It Improve Long-Term Outcomes? A Systematic Review
Smyrnis, A., Smyrnis, G., & Smyrnis, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217847 · Cited by 2
Li, H., Shen, H., Duan, X., Guo, M., & Liu, X. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07774-y · Cited by 1
Symptômes négatifs de la schizophrénie : nouvelles approches pharmacologiques
Lodovighi, M.-A., Palomba, A., Belzeaux-R, R., Adida, M., & Azorin, J. (2015) · L Encéphale · doi:10.1016/s0013-7006(16)30010-0 · Cited by 1
Kato, T. A., Ohgidani, M., Sagata, N., & Kanba, S. (2016) · Advances in Neuroimmune Biology · doi:10.3233/nib-160109 · Cited by 2
Minocycline as an Evidence-Based Adjunct Treatment in Schizophrenia
Kelly, D. L., & Wehring, H. J. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180413-01 · Cited by 1
Effectiveness of Immunotherapies for Psychotic Disorders
Upthegrove, R., & Deakin, J. F. W. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108539623.007 · Cited by 1
Neuroinflamation Treatment Options in Resistant Schizophrenia—State of the Art
de Sá, Z. C., Buinho, A., de Oliveira, T. M., Soares, F. R., Rema, J., & Novais, F. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00356-x · Cited by 1
Peyrovian, B., Palaniyappan, L. K., Kolivakis, T., & Margolese, H. C. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.70034 · Cited by 1
Präklinische Einblicke in das Zusammenspiel von Mikrobiota und Verhalten
Schmidtner, A. K., & Neumann, I. D. (2020) · Nervenheilkunde · doi:10.1055/a-1036-4206 · Cited by 1
Zinserling, V. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-96260-9_20 · Cited by 1
Nitric Oxide Synthase Mediation of Darbepoetin's Cognitive Benefits: A Paradoxical Effect?
Venkatasubramanian, G. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.270 · Cited by 1
[Anatomo-echocardiographic correlation of scimitar syndrome in adults].
Espinola-Zavaleta, N. G., Muñoz‐Castellanos, L., Játiva-Chávez, S., & Zamora-González, C. (2005) · PubMed · Cited by 4
Aretouli, E., & del Pozo, N. O. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_963 · Cited by 1
Schizophrenia and Related Psychoses
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg001.pub2 · Cited by 2
Endothelial and inflammation markers in schizophrenia and bipolar disorder
Dieset, I. (2013) · NORA - Norwegian Open Research Archives
Assessment and treatment of cognitive impairment and related features
Harvey, P. D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003872.014
Myint, A.-M., & Schwarz, M. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_10
Microglial Abnormalities in the Pathophysiology of
Monji, S., Mizoguchi, Y., & Kato, T. A. (2014)
Blood-based Biomarkers for Personalised Medicine Applications in Schizophrenia
Tomasik, J. (2014) · EUR Research Repository (Erasmus University Rotterdam)
Gomes, F. V. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2016.tde-05012016-224242
Multilevel Approaches to Schizophrenia and Other Psychotic Disorders: The Biobehavioral Interface
Walker, E. F., Ryan, A. T., Goines, K., Novacek, D. M., Goulding, S. M., Brasfield, J. L., MacDonald, A. N., & Trotman, H. D. (2016) · Wiley eBooks · doi:10.1002/9781119125556.devpsy322
Novel Approaches for Managing Schizophrenia
Rado, J. T., Hernandez, E. I., & Janicak, P. G. (2013) · Psychopharm Review · doi:10.1097/01.psyphr.0000437783.35936.18
Developmental Neuroimmune Mechanisms in Schizophrenia
Weber‐Stadlbauer, U., & Meyer, U. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622499-00046
The management of negative symptoms
Copolov, D., & Castle, D. J. (2012) · CRC Press eBooks · doi:10.3109/9781842145357.003
Mediators of neuroinflammation
Tikamdas, R., Zhang, P., & Liu, B. (2016) · Wiley eBooks · doi:10.1002/9781118832431.ch4
Lawford‐Smith, H. (2015)
Antidepressants Modulate Microglia Beyond the Neurotransmitters Doctrine of Mood Disorders
Ohgidani, M., Kato, T. A., Mizoguchi, Y., Horikawa, H., Monji, A., & Kanba, S. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_36
Vingerhoets (2017) · Research Publications (Maastricht University) · doi:10.26481/dis.20170323wv
Inflammation and subjective health : the role of sickness behaviour
Lodin, K. (2018) · Figshare
Neurocognición y biomarcadores inflamatorios en primeros episodios psicóticos
Cabrera, B. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Parker, M. (2020) · USURJ University of Saskatchewan Undergraduate Research Journal · doi:10.32396/usurj.v6i2.430
Chapitre 8. Marqueurs moléculaires et biologiques
Krebs, M. (2015) · Dunod eBooks · doi:10.3917/dunod.krebs.2015.01.0125
Recent Developments in Treating Cognitive Impairment Associated with SchizophreniaPreprint
Bittner, R. A., Barnes-Scheufler, C. V., Hettwer, M. D., Reif, A., & Qubad, M. (2021) · Preprints.org · doi:10.20944/preprints202105.0257.v1
Imunologia da esquizofrenia: evidências, perspectivas e desafios
de Campos-Carli, S. M., Salgado, J. V., & Teixeira, A. L. (2016) · Debates em Psiquiatria · doi:10.25118/2763-9037.2016.v6.136
Anti-inflammatory Agents for Patients with Schizophrenia
van Beveren, N. J. M., Çakici, N., & Sommer, I. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-71229-7_22
An effect of cholinesterase blockade on negative symptoms in schizophrenia
Ma, M., Потанин, С. С., Rupchev, G., Burminskiy, D. S., Lepilkina, T. A., & Герович, Б. А. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202112108137
da Silva, N. R. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2021.tde-05112021-105109
Krüeger, F. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108770880.017
Lee, M. R., Veerareddy, A., & Krüeger, F. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108770880.019
Current awareness in human psychopharmacology
(2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1064
Insights in the Role of Glia in Mediating Brain Plasticity in Health and Disease
Saini, V., Kaur, T., & Kaur, G. (2022) · Springer eBooks · doi:10.1007/978-981-16-8313-8_22
Metabolic disturbances in mental illness
Suat, K. (2020) · Research Publications (Maastricht University) · doi:10.26481/dis.20201214sk
Novel Approaches for Managing Schizophrenia
Janicak, P. G. (2013) · Psychopharm Review · doi:10.1097/01.psyphr.0000433989.65396.2b
Effects of Blockade of Cholinesterase on Negative Disorders in Schizophrenia
Ma, M., Потанин, С. С., Rupchev, G., Burminskiy, D. S., Lepilkina, T. A., & Герович, Б. А. (2022) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-022-01284-6
Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology
Müller, N. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_2
Más allá de lo habitual: Nuevos enfoques en la terapia de la esquizofrenia resistente
Castellanos, J. F. G., Jiménez, M. R., Bolaños-Chang, A. J., Pelayo, A. M. Z., & Meza, E. A. C. (2023) · Archives of Evidence-Based Medicine · doi:10.59706/aebmedicine.v1i2.9105
Li, S., Sakurai, K., Ohgidani, M., Kato, T. A., & Hikida, T. (2023) · Figshare · doi:10.6084/m9.figshare.23672669
Li, S., Sakurai, K., Ohgidani, M., Kato, T. A., & Hikida, T. (2023) · Figshare · doi:10.6084/m9.figshare.23672672
Li, S., Sakurai, K., Ohgidani, M., Kato, T. A., & Hikida, T. (2023) · Figshare · doi:10.6084/m9.figshare.23672666
Reactive oxygen species and psychiatric disorders
Knežević, N. N., Nenic, K., Knezevic, E., & Janković, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27333-9.00016-6
Ballendine, S. A. (2014) · HARVEST (University of Saskatchewan)
Li, S., Sakurai, K., Ohgidani, M., Kato, T. A., & Hikida, T. (2023) · Figshare · doi:10.6084/m9.figshare.23672675
Tetracycline antibiotics: Emerging roles in neuropsychiatric disorders
Acar, A. Ş., Saday, Ö., & Erbaş, O. (2024) · Demiroglu Science University Florence Nightingale Journal of Medicine · doi:10.5606/fng.btd.2024.149
From neuroinflammation to neural inference: computational psychiatry meets precision medicine
Mansour, G. K., & Hajjar, A. W. (2026) · Schizophrenia · doi:10.1038/s41537-026-00757-8
Metadata
- Authors
- Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S.
- Affiliations
- Shalvata Mental Health Center (IL)
- Corresponding author
- Levkovitz, Yechiel
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-11-03
- Volume
- 71
- Issue
- 02
- Pages
- 138-149
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2084588595
- Cited by
- 387
- References
- 112
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 10 · 2023: 17 · 2022: 16 · 2021: 23 · 2020: 26 · 2019: 22 · 2018: 26 · 2017: 15 · 2016: 33 · 2015: 42 · 2014: 34 · 2013: 44 · 2012: 27
- FWCI
- 13.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- minocycline, early-phase schizophrenia, negative symptoms, cognitive impairment, executive function, adjunctive therapy, glutamatergic system, nitric oxide synthase inhibition, microglial activation, atypical antipsychotics, Scale for the Assessment of Negative Symptoms
- MeSH terms
- Adolescent, Adult, Cognition, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Minocycline, Placebos, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
